RVNC•benzinga•
HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Raises Price Target to $29
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga